Oral News and Research

RSS

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.

18 Jun 2014

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

The last 20 years have been defined by progress and innovation in the multiple sclerosis (MS) field, with now 10 approved treatment options available for people living with relapsing MS, the most common form of the disease.

17 Jun 2014

Childhood oestrogen may normalise thelarche in Turner syndrome

Treating girls with Turner syndrome with low-dose oestrogen from childhood results in earlier thelarche and a slower tempo of puberty, research shows.

16 Jun 2014

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

16 Jun 2014

Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Researchers from Case Western Reserve University in Cleveland have discovered that populating the gastrointestinal (GI) tracts of mice with Bacteroides species producing a specific enzyme helps protect the good commensal bacteria from the harmful effects of antibiotics.

13 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death compared with those who take a combination of metformin plus sulfonylurea, according to a new study funded by the Agency for Healthcare Research and Quality that appears in the June 11 issue of JAMA.

11 Jun 2014

New framework for monitoring oral cancer development, progression, recurrence

Each year, approximately 22,000 Americans are diagnosed with oral cancer. The five-year survival rate of 40% in the U.S. is one of the lowest of the major cancers, and it has not improved in the past 40 years.

11 Jun 2014

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

10 Jun 2014

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.

10 Jun 2014

Merck enters into definitive agreement with Idenix

Merck, known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc., today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

9 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

9 Jun 2014

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

6 Jun 2014

Disinfection caps, 'scrub-the-hub' regimens reduce bloodstream infections, cut costs

Whether through the use of alcohol-containing caps or basic cleaning of the injection port of the central line, infection preventionists at three hospitals are finding successful ways to stop germs from entering central line catheters and causing bloodstream infections in patients.

6 Jun 2014

Study offers clues to best long-acting injectable antipsychotic use

Findings from the PROACTIVE study suggest why the benefits of long-acting injectable second-generation antipsychotics may be difficult to detect in a clinical trial.

5 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Flu vaccination of healthcare workers protects broader community, shows study

For every 15 healthcare providers who receive the influenza vaccination, one fewer person in the community will contract an influenza-like illness, according to a study using California public health data from 2009 - 2012.

5 Jun 2014

Oral News and Research

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Childhood oestrogen may normalise thelarche in Turner syndrome

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

New framework for monitoring oral cancer development, progression, recurrence

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

Merck enters into definitive agreement with Idenix

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Disinfection caps, 'scrub-the-hub' regimens reduce bloodstream infections, cut costs

Study offers clues to best long-acting injectable antipsychotic use

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Flu vaccination of healthcare workers protects broader community, shows study

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News